
Viking Therapeutics (VKTX) Stock Forecast & Price Target
Viking Therapeutics (VKTX) Analyst Ratings
Bulls say
Viking Therapeutics is a healthcare provider specializing in biopharmaceutical development for metabolic and endocrine disorders, with a promising clinical pipeline including VK2809, VK5211, and VK0214. This positive outlook is supported by efficient oral programs, smaller and shorter studies, a proactive approach towards manufacturing and supply, and the expansion into alternative PBM relationships. Additionally, Viking's strong cash runway, ongoing BD discussions, and potential partnerships further enhance its strategic flexibility and long-term value proposition.
Bears say
Viking Therapeutics is facing potential challenges in patient tolerability with their drug VK2809, as evidenced by high drop-out rates in clinical trials, and are expanding their commercial strategy in hopes of achieving only a 5-10% market share due to anticipated competition. Their quarterly report shows low revenue and high operating expenses, leading to significant net losses.
This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Viking Therapeutics (VKTX) Analyst Forecast & Price Prediction
Start investing in Viking Therapeutics (VKTX)
Order type
Buy in
Order amount
Est. shares
0 shares